TAFLOTAN-S OPHTHALMIC SOLUTION 0.0015%

Land: Singapúr

Tungumál: enska

Heimild: HSA (Health Sciences Authority)

Virkt innihaldsefni:

Tafluprost

Fáanlegur frá:

SANTEN PHARMACEUTICAL ASIA PTE. LTD.

ATC númer:

S01EE05

Lyfjaform:

SOLUTION, STERILE

Samsetning:

Tafluprost 0.015mg

Stjórnsýsluleið:

OPHTHALMIC

Gerð lyfseðils:

Prescription Only

Framleitt af:

Santen Pharmaceutical Co Ltd (Noto Plant)

Leyfisstaða:

ACTIVE

Leyfisdagur:

2015-09-23

Vara einkenni

参天製薬　756731　MU_タフロタン点眼液(シンガポール)添付文書
2860-02〈06〉ｵﾓﾃ（21/09/03）
420×120　1° コン　　大光印刷株式会社
Composition
Taflotan ophthalmic solution 0.0015% is a clear, colorless, sterile
aqueous ophthalmic solution. Each
mL contains 15μg of tafluprost. It also contains Polysorbate 80,
concentrated glycerin, disodium
edetate hydrate, sodium dihydrogen phosphate dihydrate, benzalkonium
chloride and pH adjuster
(sodium hydroxide, hydrochloric acid) as additives. Its pH is 5.7 -
6.3 and its osmolar ratio is 1.0 - 1.1.
Indications
Reduction of intraocular pressure in patients with primary open-angle
glaucoma or ocular
hypertension.
Dosage and Administration
Instill 1 drop in the affected eye(s) once daily.

Do not use more than once daily because more frequent administration
may lessen the IOP-lowering
effect.
Pharmacology
1.Intraocular pressure (IOP) lowering effect
Ocular administration of tafluprost ophthalmic solutions ranged from
0.00002% to 0.005% in a
single dose to monkeys showed the IOP lowering effect in a
concentration-dependent manner.
The effect was statistically significant in the groups of the
concentration of 0.0005% and higher,
compared with the vehicle group. In a repeated dose study in monkeys
of tafluprost ophthalmic
solutions ranged from 0.001% to 0.005% once daily for 5 days, IOP
lowering effect at every
concentration was stable and did not attenuate during the
administration period.
2.Mechanism of action
Tafluprost acid form, an active metabolite, showed high affinity for
the prostanoid FP receptor
(Ki=0.40 nM). Aqueous humor dynamics in monkeys was evaluated using
fluorophotometry,
two-level constant pressure perfusion and
125
I-
131
I labelled albumin perfusion methods following
the repeated administration of 0.005% tafluprost ophthalmic solution
once daily for 3 to 5 days.
Uveoscleral outflow significantly increased without any change in
aqueous production.
3.Effect on ocular blood flow
(1)
A repeated installati